16d agoStocktwits NewsBULLISH 71Analyst
BIIB Stock Jumps 5% — Analysts Raise Price Targets After FDA Clears Alzheimer’s Treatment For At-Home Use
The decision marks a major shift in how patients can begin therapy for early Alzheimer’s disease.
Archived explainer. For the current picture see today's BIIB page.
Why Is BIOGEN INC (BIIB) Stock Up Today?
By the Top Tier Newswire AI Desk · July 13, 2026 at 3:46 PM ET · reviewed against 8 wire stories
BIOGEN INC (BIIB) is up +5.26% in the latest session. Our newswire has captured 8 stories on BIIB across 6 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Biogen Inc. stock rose 5.26% to $209.63 on Thursday, driven by positive developments in the company’s Alzheimer’s drug pipeline and analyst upgrades. The FDA’s recent approval of at-home administration for Leqembi, Biogen’s Alzheimer’s treatment, has shifted the treatment landscape for early-stage patients. Analysts have also raised price targets in response to the regulatory progress and upcoming data presentations.
What Happened
Stocktwits News reported that BIIB stock jumped 5% as analysts raised price targets following the FDA’s decision to allow at-home use of the Alzheimer’s treatment. Barron’s noted a key upgrade to "Buy" for Biogen stock, citing expectations that the market will respond positively to detailed data on its experimental Alzheimer’s drug. Yahoo Finance highlighted that Biogen was upgraded by Wall Street analysts, adding to the momentum. Additionally, new clinical data from the Alzheimer’s Association International Conference 2026 showed that the subcutaneous autoinjector version of Leqembi achieved similar efficacy and safety to the IV formulation, reinforcing the potential for at-home treatment options.
What The Data Shows
The stock traded up 5.26% despite a recent 8-session price decline of 4.9%. The average AI sentiment across eight stories from six sources in the last 36 hours was 63 out of 100, indicating a generally positive tone. The stock’s market cap stands at $29.4B, with a P/E ratio of 21.4 and a revenue increase of 1.2% in the trailing twelve months. Congressional trades show 7 buys and 1 sell in the last 90 days, with the most recent filing on July 7, 2026.
What To Watch
Biogen will present detailed Phase 2 study data for its experimental Alzheimer’s drug diranersen at a conference in London. Investors should monitor the reception of this data and the broader market reaction to the upcoming subcutaneous administration pathway for Leqembi.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
BIIB by the numbers
Last: $209.63Session: +5.26%7 sessions: -4.94%Coverage: 8 stories / 6 sourcesAI sentiment: 63/100 (bullish)Mkt cap: $29.4BP/E: 21.452w: $121.05 to $219.72
The headlines behind the move
16d agoYahoo FinanceBULLISH 61Analyst
American Express, Biogen upgraded: Wall Street's top analyst calls
American Express, Biogen upgraded: Wall Street
16d agoBarron'sBULLISH 61Analyst
Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study Details
Biogen stock receives a bullish upgrade based on expectations the market will cheer the company’s detailed data on its experimental Alzheimer’s drug.
16d agoYahoo TopBULLISH 55Analyst
Here Are Monday’s Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John’s International, Shopify, and More
Pre-Market Stock Futures: Futures are trading lower as we get ready for the start of second-quarter earnings this week, after a solid winning week on Wall Street. Renewed strikes against Iran and a chip sell-off are weighing on shares on Monday. All of the major indices closed higher on Friday, except the small-cap Russell 2000, ... Here Are Monday’s Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John’s International, Shopify, and More
16d agoStockTitanBULLISH 63Product/PR
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer | BIIB Stock News
Thomas McCauley, Ph.D., with 25+ years leading R&D and genetic medicine programs, is appointed Chief Scientific Officer to guide Stoke’s RNA platform.
17d agoBarron'sBULLISH 56Product/PR
Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer's?
Biogen will present detailed Phase 2 study data for its experimental Alzheimer’s drug diranersen at a conference in London.
17d agoStockTitanBULLISH 73Product/PR
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026 | BIIB Stock News
New AAIC 2026 data show weekly 500 mg LEQEMBI subcutaneous autoinjector achieves 104% exposure vs. IV and low 1.4% antibody rate, backing an at‑home option if approved.
17d agoPR NewswireBULLISH 63Product/PR
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026
New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners TOKYO and CAMBRIDGE, Mass., July 12, 2026 /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB)...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on BIIB: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier BIIB move explainers: 2026-07-14 · 2026-07-13